To determine the effects of CREB3L4 on the HCC chemosensitivity to sorafenib in vivo, the xenografted LV-shCREB3L4 or LV-shNC tumor models were treated with sorafenib or PBS, respectively. Here, CREB3L4 is linked to hepatocellular carcinoma.